The December, 2016 issue of  THORACIC ONCOLOGY TRANSLATIONAL RESEARCH AT UCLA & TRIO-US announces that the National Cancer Institute has awarded funding to study determinants of benefit from PD-1 inhibitors in patients at UCLA (including satellite sites) and the TRIO US Network for the proposal, “A model for predicting response to PD-(L)1 inhibitors in Non-Small Cell Lung Cancer.”

The UCLA team plans to use a tissue bank to evaluate clinical characteristics and properties of tumors and the immune microenvironment that predict benefit from immune checkpoint inhibition.